In a patient whose behavior improves with clozapine after multiple medication failures but who now has tachycardia with a heart rate of 125 bpm, what should be done?

Management of Clozapine-Induced Tachycardia (HR 125 bpm)

Continue clozapine and add a beta-blocker (atenolol or bisoprolol) or ivabradine to manage the persistent tachycardia, as the psychiatric benefit in this treatment-resistant patient outweighs the cardiovascular risk when appropriately monitored and treated. 1

Immediate Assessment Required

First, determine the timing and context of this tachycardia:

• Rule out myocarditis: Check if this occurred within the first few months of clozapine initiation. If accompanied by fever, chest pain, malaise, myalgias, or elevated troponin/CRP, suspect myocarditis and obtain urgent cardiology consultation with echocardiogram 2, 3
• Assess for other cardiac pathology: Obtain ECG to evaluate for arrhythmias (supraventricular tachycardia can occur with clozapine) 4, 5
• Check clozapine level: Ensure the level is therapeutic and not toxic, as higher levels correlate with higher heart rates 1

Understanding the Clinical Context

Tachycardia with clozapine is extremely common—68% of patients develop it 1. In your patient with treatment-resistant schizophrenia who has failed multiple medications and is now responding to clozapine, discontinuing this medication would likely result in psychiatric decompensation with significant morbidity. The 2026 Lancet Psychiatry consensus guidelines explicitly address this scenario and provide clear management strategies.

Treatment Algorithm

If Myocarditis is Ruled Out:

Step 1: Pharmacologic Management of Tachycardia

• Initiate a beta-blocker (atenolol or bisoprolol) OR ivabradine 1
• Beta-blockers are first-line based on the guideline recommendations and have been successfully used in case reports 6, 2
• Ivabradine is an alternative "tonic agent" specifically mentioned in guidelines 1

Step 2: If Tachycardia Persists Despite Beta-Blocker

• Consider reducing the clozapine dose while adding an adjunctive antipsychotic (aripiprazole or lurasidone have been used successfully) 6
• This approach maintains psychiatric stability while reducing cardiovascular burden
• A case report demonstrated successful stabilization using clozapine dose reduction plus lurasidone 6

Step 3: Optimize Clozapine Dosing

• Review if slower titration is still possible (if early in treatment) 1
• Ensure the patient is on the minimum effective dose for psychiatric control
• Check for drug interactions that may be increasing clozapine levels (CYP1A2 inhibitors, smoking cessation) 1

Monitoring Requirements

• Heart rate monitoring: Should be routine and ongoing 1
• Annual ECG: Should be considered (though not mandated by consensus) 1
• Echocardiogram: Only if clinically indicated (symptoms of heart failure, elevated troponin, or other concerning features)—NOT routinely 1
• Clozapine levels: Check annually and with any change in clinical status 1

Critical Pitfalls to Avoid

1. Do not use Bazett's formula for QTc correction in clozapine patients—it overcorrects for tachycardia and falsely suggests QT prolongation. Use Fredericia, Hodges, or QT nomogram instead 7

2. Do not discontinue clozapine prematurely for isolated tachycardia without attempting pharmacologic management first. In treatment-resistant schizophrenia, the psychiatric morbidity of stopping effective clozapine typically exceeds the cardiovascular risk of managed tachycardia 6, 8

3. Do not miss myocarditis: If tachycardia is accompanied by fever, chest pain, elevated troponin, or occurs in the first few months of treatment, this is myocarditis until proven otherwise 1, 2, 3

4. Tachycardia is often clinically unnoticed—33% of clozapine patients have HR >100, but many receive no treatment 8. Active monitoring is essential.

Multidisciplinary Approach

Coordinate care between psychiatry and cardiology 6. The cardiologist can help optimize heart rate control with appropriate cardiac medications while you maintain psychiatric stability. This collaborative approach allows continuation of life-saving psychiatric treatment while managing cardiovascular side effects.

The key principle: In treatment-resistant schizophrenia with good clozapine response, manage the tachycardia pharmacologically rather than discontinuing the only effective psychiatric medication.